This Stock Could Be a Surprise Growth Pick for 2021

A lot of people have written off Amarin (NASDAQ: AMRN) for dead. The stock sells for a little over three times revenue and three times the cash on the books.

The biotech only has one drug, Vascepa. It's an amazing medication that reduces strokes and heart attacks among patients on statin therapy. Dr. Deepak Bhatt, professor of medicine at Harvard, says Vascepa "represents one of the most important developments in the prevention and treatment of cardiovascular disease since statins."

Image source: Getty Images.

Continue reading

Source Fool.com